^
Association details:
| Biomarker: | KEAP1 deletion + KRAS mutation |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
Impact of STK11 and/or KEAP1 Deletion on Outcomes to Immunotherapy in Non-Small Cell Lung Cancer
Published date:
01/28/2023
Excerpt:
...we identified 717 patients with advanced non-squamous NSCLC who received ICI monotherapy…in KRASMUT NSCLC, but not KRASWT NSCLC, KEAP1DEL was associated with a lower ORR (0% vs 31%, p=0.004), shorter PFS (HR 1.8, p=0.03), and shorter OS (HR 2.5, p=0.001) to immunotherapy….STK11 and KEAP1 deletion may be linked to generally worse outcomes to ICI in KRASMUT NSCLC.
